USANA Health Sciences Stock Price, News & Analysis (NYSE:USNA)

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" USNA shares.
View USNA analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued twelve-month price targets for USANA Health Sciences' shares. Their USNA share price targets range from $53.00 to $53.00. On average, they anticipate the company's share price to reach $53.00 in the next year. This suggests a possible upside of 12.1% from the stock's current price.
View analysts price targets for USNA or view top-rated stocks among Wall Street analysts.

USANA Health Sciences' stock was trading at $53.20 on January 1st, 2023. Since then, USNA shares have decreased by 11.2% and is now trading at $47.26.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our USNA earnings forecast.

USANA Health Sciences, Inc. (NYSE:USNA) issued its earnings results on Tuesday, October, 24th. The company reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.64 by $0.05. The firm had revenue of $213.37 million for the quarter, compared to the consensus estimate of $212.24 million. USANA Health Sciences had a net margin of 6.45% and a trailing twelve-month return on equity of 13.08%.

ETFs with the largest weight of USANA Health Sciences (NYSE:USNA) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), Roundhill Acquirers Deep Value ETF (DEEP), Global X Health & Wellness ETF (BFIT), ETC 6 Meridian Low Beta Equity Strategy ETF (SIXL),

USANA Health Sciences updated its FY23 earnings guidance on Tuesday, October, 24th. The company provided earnings per share (EPS) guidance of $2.80-3.05 for the period, compared to the consensus estimate of $3.13. The company issued revenue guidance of $900-920 million, compared to the consensus revenue estimate of $930.04 million.

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

USANA Health Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Pzena Investment Management LLC (4.08%), Charles Schwab Investment Management Inc. (1.11%), Acadian Asset Management LLC (0.90%), American Century Companies Inc. (0.71%), Invesco Ltd. (0.64%) and Bank of New York Mellon Corp (0.60%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood, Walter Noot and Xia Ding.
View institutional ownership trends.

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.